CS
TEVA icon

Credit Suisse’s Teva Pharmaceuticals TEVA Stock Holding History

Credit Suisse’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$13.7M Sell
973,484
-290,641
-23% -$3.66M 0.01% 782
2023
Q4 		$13.2M Buy
1,264,125
+48,930
+4% +$457K 0.01% 800
2023
Q3 		$12.4M Sell
1,215,195
-247,249
-17% -$2.3M 0.01% 813
2023
Q2 		$11M Sell
1,462,444
-175,473
-11% -$1.42M 0.01% 880
2023
Q1 		$14.5M Sell
1,637,917
-4,170,063
-72% -$41.2M 0.01% 790
2022
Q4 		$53M Sell
5,807,980
-1,610,942
-22% -$14.1M 0.06% 375
2022
Q3 		$59.9M Buy
7,418,922
+524,548
+8% +$4.64M 0.07% 314
2022
Q2 		$51.8M Buy
6,894,374
+137,322
+2% +$1.2M 0.05% 373
2022
Q1 		$63.4M Sell
6,757,052
-89,830
-1% -$750K 0.05% 367
2021
Q4 		$54.8M Sell
6,846,882
-196,733
-3% -$1.78M 0.03% 597
2021
Q3 		$68.6M Sell
7,043,615
-103,935
-1% -$973K 0.04% 512
2021
Q2 		$71.7M Buy
7,147,550
+2,780,234
+64% +$29.4M 0.04% 507
2021
Q1 		$50.4M Sell
4,367,316
-2,580,276
-37% -$29.6M 0.03% 697
2020
Q4 		$67M Sell
6,947,592
-1,440,130
-17% -$13.8M 0.03% 574
2020
Q3 		$75.6M Buy
8,387,722
+366,320
+5% +$3.88M 0.05% 440
2020
Q2 		$98.9M Sell
8,021,402
-330,513
-4% -$3.74M 0.07% 287
2020
Q1 		$75M Buy
8,351,915
+1,500,345
+22% +$15.4M 0.06% 295
2019
Q4 		$67.1M Sell
6,851,570
-4,040,590
-37% -$36.1M 0.05% 415
2019
Q3 		$74.9M Buy
10,892,160
+3,719,394
+52% +$28.5M 0.06% 313
2019
Q2 		$66.2M Buy
7,172,766
+4,029,506
+128% +$48.6M 0.06% 336
2019
Q1 		$49.3M Buy
3,143,260
+1,628,404
+107% +$28.7M 0.05% 431
2018
Q4 		$23.4M Sell
1,514,856
-826,456
-35% -$16.9M 0.02% 713
2018
Q3 		$50.4M Sell
2,341,312
-995,600
-30% -$23.1M 0.05% 421
2018
Q2 		$81.2M Buy
3,336,912
+383,166
+13% +$7.81M 0.08% 238
2018
Q1 		$50.5M Buy
2,953,746
+500,845
+20% +$9.78M 0.05% 411
2017
Q4 		$46.5M Buy
2,452,901
+1,124,102
+85% +$16.9M 0.04% 453
2017
Q3 		$23.4M Buy
1,328,799
+181,496
+16% +$4.08M 0.02% 738
2017
Q2 		$38.1M Buy
1,147,303
+78,683
+7% +$2.44M 0.04% 508
2017
Q1 		$34.3M Buy
1,068,620
+40,358
+4% +$1.38M 0.03% 569
2016
Q4 		$37.3M Buy
1,028,262
+694,678
+208% +$27.7M 0.04% 523
2016
Q3 		$15.3M Sell
333,584
-390,011
-54% -$20.3M 0.01% 958
2016
Q2 		$36.3M Buy
723,595
+431,760
+148% +$23M 0.04% 503
2016
Q1 		$15.6M Sell
291,835
-396,566
-58% -$23.3M 0.02% 849
2015
Q4 		$45.2M Sell
688,401
-174,982
-20% -$10.8M 0.05% 412
2015
Q3 		$48.7M Buy
863,383
+140,792
+19% +$9.13M 0.06% 367
2015
Q2 		$42.7M Sell
722,591
-327,837
-31% -$20.2M 0.04% 493
2015
Q1 		$65.4M Sell
1,050,428
-114,316
-10% -$6.65M 0.07% 314
2014
Q4 		$67M Sell
1,164,744
-883,043
-43% -$49.2M 0.06% 338
2014
Q3 		$110M Buy
2,047,787
+440,053
+27% +$23.3M 0.09% 222
2014
Q2 		$84.3M Buy
1,607,734
+47,200
+3% +$2.41M 0.07% 277
2014
Q1 		$82.5M Buy
1,560,534
+520,565
+50% +$24.1M 0.08% 247
2013
Q4 		$41.7M Buy
1,039,969
+613,937
+144% +$24.2M 0.04% 482
2013
Q3 		$16.1M Sell
426,032
-355,185
-45% -$13.9M 0.02% 866
2013
Q2 		$30.6M Buy
+781,217
New +$30.4M 0.03% 559

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Credit Suisse's TEVA Position: Q1 2024 in Review

Credit Suisse reduced its Teva Pharmaceuticals (TEVA) stake by 23% in Q1 2024, selling an estimated $3.66M and leaving 973,484 shares worth $13.7M. The position accounts for 0.01% of the portfolio, ranked #782.

Credit Suisse first reported a position in TEVA in Q2 2013 and has held it in 44 quarters since. The position peaked at $110M in Q3 2014. 481 funds tracked by Wall St. Rank hold TEVA as of Q1 2024.

  • Credit Suisse held 973,484 shares of Teva Pharmaceuticals worth $13.7M as of Q1 2024.
  • Credit Suisse sold 290,641 Teva Pharmaceuticals shares in Q1 2024, an estimated $3.66M.
  • Teva Pharmaceuticals made up 0.01% of Credit Suisse's portfolio in Q1 2024, its #782 holding.
  • Credit Suisse first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 44 quarters since.
  • Credit Suisse's Teva Pharmaceuticals position peaked at $110M in Q3 2014.
  • 481 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.